Viewing Study NCT04220866

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 4:25 PM
Ignite Modification Date: 2026-02-22 @ 5:09 PM
Study NCT ID: NCT04220866
Status: COMPLETED
Last Update Posted: 2025-10-29
First Post: 2020-01-06
Is NOT Gene Therapy: True
Has Adverse Events: True
Brief Title: Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)
Sponsor: Merck Sharp & Dohme LLC
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Head and Neck Squamous Cell Carcinoma (HNSCC) View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Programmed Cell Death-1 (PD1, PD-1) View
None Programmed Death-Ligand 1 (PDL1, PD-L1) View
None intratumoral (IT) View
None metastatic View
None unresectable View
None recurrent View
None ulevostinag View
None pembrolizumab View